How to access Vumerity from Jordan, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Jordanian patient with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease, may receive a prescription for Vumerity (diroximel fumarate) from their treating neurologist. Vumerity is FDA-approved for relapsing MS and developed by Biogen. It is not a controlled substance. In Jordan, Vumerity is not routinely registered for outpatient dispensing, and access is typically coordinated through the named-patient import pathway.

This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Vumerity is an oral fumarate taken twice daily (titrated over one week from 231 mg to maintenance 462 mg twice daily). Diroximel fumarate is a prodrug of monomethyl fumarate, the same active metabolite as dimethyl fumarate (Tecfidera), with an improved GI tolerability profile in comparative studies. Eligibility anchors to confirmed relapsing MS diagnosis (McDonald criteria), baseline MRI, and monitoring plan for the class-level concerns, lymphopenia, liver enzymes, and PML risk stratification (JC virus antibody testing where indicated).

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Is Vumerity legally importable into Jordan?

Yes, through the Jordan Food and Drug Administration (JFDA) named-patient / special-access import framework. The mechanism permits a Jordanian-licensed physician to import a medicine not locally registered when (a) it is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable (dimethyl fumarate may be considered; diroximel's GI-tolerability profile is distinct), (c) the physician accepts clinical responsibility, and (d) chain of custody is documented.

How the pathway works, step by step

1. Consultation with your treating neurologist. MS diagnosis per McDonald criteria, MRI documentation, relapse history, and clinical rationale.
2. Baseline assessment. Complete blood count with differential (lymphocyte monitoring), hepatic panel, JC virus antibody status, pregnancy planning discussion where applicable.
3. JFDA named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, titration plan, and chain-of-custody commitment.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Vumerity from authorised distribution under DSCSA.
5. Ambient shipment. Vumerity ships under controlled ambient conditions with chain-of-custody documentation.
6. Arrival and dispensing. The hospital pharmacy releases the bottles with titration instructions and monitoring schedule.

What documentation your physician needs

• Clinical rationale letter confirming relapsing MS and Vumerity as the indicated therapy
• Verification of Jordanian medical license
• MRI report and McDonald-criteria documentation
• Baseline CBC with differential, hepatic panel, JC virus antibody status
• Planned titration schedule and safety monitoring plan (lymphocytes, LFTs)
• Pregnancy planning discussion documentation where applicable

Reserve Meds provides a physician documentation kit bundling templates JFDA reviewers expect for MS disease-modifying therapy named-patient imports.

Costs and timing

Vumerity's US cash-pay drug-only reference cost sits in an indicative 2026 annual range of roughly USD 100,000-110,000 for continuous daily dosing. International logistics, JFDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. Indicative range.

Indicative timing for first dispense after cohort intake opens is 7-14 days from the moment a complete JFDA application is submitted.

If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and JFDA review.
• Logistics. Ambient-controlled shipment to your prescribing hospital.
• Concierge case lead. A named point of contact coordinating monthly refills and monitoring-cadence reminders.

What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

Frequently asked

Is this legal in Jordan? Yes, when executed through the JFDA named-patient framework with appropriate documentation. See our trust and compliance page.

Is Vumerity a controlled substance? No. Diroximel fumarate is not a scheduled controlled substance.

How does Vumerity compare with Tecfidera? Both convert to monomethyl fumarate in vivo; Vumerity (diroximel fumarate) demonstrated a reduced incidence of GI adverse events in head-to-head studies, which can meaningfully affect adherence.

What monitoring is required? CBC with differential (lymphopenia can develop and warrants caution), hepatic enzymes, and JC virus antibody status per PML-risk monitoring, your neurologist sets the full cadence.

Will insurance cover this? Cash-pay is the default. Some Jordanian private insurers consider case by case; we supply documentation but do not process claims directly.

Next step

Or download the PDF guide ›

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds AI Clinical and Regulatory Review (see /trust). Last medically reviewed: 2026-04-23.